{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:12:15Z","timestamp":1793686335332,"version":"4.5.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic kidney disease (CKD) is a significant comorbidity in patients with rheumatoid arthritis (RA). The relative contributions of inflammatory and traditional renal risk factors to CKD progression remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>\n                      We retrospectively analyzed 601 RA patients. Renal function and urinary abnormalities were assessed using creatinine-based estimated glomerular filtration rate (eGFR) and urinary albumin. We examined the factors associated with high or very high CKD risk in KDIGO heatmap and progression of CKD stage over five years using two models: logistic regression and Cox proportional hazards models. Furthermore, Propensity score methods were used to assess the association between methotrexate (MTX) use and CKD stage progression\n                      <jats:bold>.<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CKD stage progression occurred in 106 patients. Both inflammatory and traditional renal risk factors were associated with high or very high CKD risk. In Cox analyses, age, lower baseline eGFR, anemia, and CRP \u22650.5\u00a0mg\/dL were associated with CKD stage progression. In patients with baseline eGFR \u226560\u00a0mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      , CRP \u22650.5\u00a0mg\/dL was independently associated with progression, whereas proteinuria and albuminuria were more relevant in patients with baseline eGFR &lt;60\u00a0mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      . After adjusting for confounding variables using propensity score matching, there was no association between MTX use and an increased risk of kidney stage progression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Risk factors for CKD progression in RA may differ according to baseline eGFR. In patients with preserved eGFR, residual inflammation appears to be a relevant factor. In contrast, proteinuria, albuminuria, and anemia are more significant in patients with reduced eGFR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10157-026-02937-3","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T12:30:52Z","timestamp":1788006652000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Inflammatory and traditional risk factors associated with the progression of chronic kidney disease in patients with rheumatoid arthritis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6332-0146","authenticated-orcid":false,"given":"Masafumi","family":"Sugiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayo","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Tsuchimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Tsuchimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chise","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"2937_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01525-8","author":"A Di Matteo","year":"2023","unstructured":"Di Matteo A, Bathon JM, Emery P. Rheumatoid arthritis. Lancet. 2023. https:\/\/doi.org\/10.1016\/S0140-6736(23)01525-8.","journal-title":"Lancet"},{"issue":"12","key":"2937_CR2","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/s41584-024-01169-7","volume":"20","author":"V Konzett","year":"2024","unstructured":"Konzett V, Aletaha D. Management strategies in rheumatoid arthritis. Nature Reviews Rheumatology. Nat Res. 2024;20(12):760\u20139. https:\/\/doi.org\/10.1038\/s41584-024-01169-7.","journal-title":"Nat Res"},{"key":"2937_CR3","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1136\/ard.46.9.658","volume":"46","author":"M Boers","year":"1987","unstructured":"Boers M, Croonen AM, Dijkmans BAC, Breedveld FC, Eulderink F, Cats A, et al. Renal findings in rheumatoid arthritis: clinical aspects of 132 necropsies. Ann Rheum Dis. 1987;46:658\u201363. https:\/\/doi.org\/10.1136\/ard.46.9.658.","journal-title":"Ann Rheum Dis"},{"key":"2937_CR4","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1007\/s10067-019-04649-4","volume":"38","author":"NA Shadick","year":"2019","unstructured":"Shadick NA, Gerlanc NM, Frits ML, Stolshek BS, Brady BL, Iannaccone C, et al. The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry. Clin Rheumatol. 2019;38:3081\u201392. https:\/\/doi.org\/10.1007\/s10067-019-04649-4.","journal-title":"Clin Rheumatol"},{"key":"2937_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae228","author":"S Maruyama","year":"2024","unstructured":"Maruyama S, Tanaka T, Akiyama H, Hoshino M, Inokuchi S, Kaneko S, et al. Cardiovascular, renal and mortality risk by the KDIGO heatmap in Japan. Clin Kidney J. 2024. https:\/\/doi.org\/10.1093\/ckj\/sfae228.","journal-title":"Clin Kidney J"},{"key":"2937_CR6","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","volume":"105","author":"A Levin","year":"2024","unstructured":"Levin A, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns. Kidney Int. 2024;105:684\u2013701. https:\/\/doi.org\/10.1016\/j.kint.2023.10.016.","journal-title":"Kidney Int"},{"key":"2937_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15010108","author":"K Ichinose","year":"2026","unstructured":"Ichinose K. The interplay between rheumatoid arthritis and chronic kidney disease from mechanisms to treatment. J Clin Med Multidiscip Dig Publish Inst. 2026. https:\/\/doi.org\/10.3390\/jcm15010108.","journal-title":"J Clin Med Multidiscip Dig Publish Inst"},{"key":"2937_CR8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1756-185X.2011.01594.x","volume":"14","author":"M Haroon","year":"2011","unstructured":"Haroon M, Adeeb F, Devlin J, O\u2019Gradaigh D, Walker F. A comparative study of renal dysfunction in patients with inflammatory arthropathies: Strong association with cardiovascular diseases and not with anti-rheumatic therapies, inflammatory markers or duration of arthritis. Int J Rheum Dis. 2011;14:255\u201360. https:\/\/doi.org\/10.1111\/j.1756-185X.2011.01594.x.","journal-title":"Int J Rheum Dis"},{"key":"2937_CR9","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s10157-016-1309-1","volume":"21","author":"D Inaguma","year":"2017","unstructured":"Inaguma D, Imai E, Takeuchi A, Ohashi Y, Watanabe T, Nitta K, et al. Risk factors for CKD progression in Japanese patients: findings from the Chronic Kidney Disease Japan Cohort (CKD-JAC) study. Clin Exp Nephrol. 2017;21:446\u201356. https:\/\/doi.org\/10.1007\/s10157-016-1309-1.","journal-title":"Clin Exp Nephrol"},{"key":"2937_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160225","author":"M Kochi","year":"2016","unstructured":"Kochi M, Kohagura K, Shiohira Y, Iseki K, Ohya Y. Inflammation as a risk of developing chronic kidney disease in rheumatoid arthritis. PLoS One. 2016. https:\/\/doi.org\/10.1371\/journal.pone.0160225.","journal-title":"PLoS One"},{"key":"2937_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1053\/j.ajkd.2012.07.007","volume":"61","author":"M Horio","year":"2013","unstructured":"Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S. GFR estimation using standardized serum cystatin C in Japan. Am J Kidney Dis. 2013;61:197\u2013203. https:\/\/doi.org\/10.1053\/j.ajkd.2012.07.007.","journal-title":"Am J Kidney Dis"},{"key":"2937_CR12","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392. https:\/\/doi.org\/10.1053\/j.ajkd.2008.12.034.","journal-title":"Am J Kidney Dis"},{"key":"2937_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transplant"},{"key":"2937_CR14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/jdi.14293","volume":"16","author":"K Asahi","year":"2025","unstructured":"Asahi K, Konta T, Tamura K, Tanaka F, Fukui A, Nakamura Y, et al. The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese patients with type 2 diabetes. J Diabetes Investig. 2025;16:108\u201319. https:\/\/doi.org\/10.1111\/jdi.14293.","journal-title":"J Diabetes Investig"},{"key":"2937_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf391","author":"M Ausserwinkler","year":"2026","unstructured":"Ausserwinkler M, Kronbichler A, Gensluckner S, Aberger S, Paulweber B, Trinka E, et al. Association of rheumatoid arthritis with chronic kidney disease. Clin Kidney J. 2026. https:\/\/doi.org\/10.1093\/ckj\/sfaf391.","journal-title":"Clin Kidney J"},{"key":"2937_CR16","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s10157-014-1034-6","volume":"19","author":"K Nagai","year":"2015","unstructured":"Nagai K, Yamagata K. Quantitative evaluation of proteinuria for health checkups is more efficient than the dipstick method. Clin Exp Nephrol. 2015;19:152\u20133. https:\/\/doi.org\/10.1007\/s10157-014-1034-6.","journal-title":"Clin Exp Nephrol"},{"key":"2937_CR17","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/ndt\/gfad195","volume":"39","author":"H Kim","year":"2024","unstructured":"Kim H, Hyun YY, Joo YS, Yun HR, Kim Y, Jung JY, et al. Proteinuria, measured or estimated albuminuria for risk prediction in patients with chronic kidney disease? Nephrol Dial Transplant. 2024;39:473\u201382. https:\/\/doi.org\/10.1093\/ndt\/gfad195.","journal-title":"Nephrol Dial Transplant"},{"key":"2937_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-86541-333846379","author":"DR Chang","year":"2021","unstructured":"Chang DR, Yeh HC, Ting IW, Lin CY, Huang HC, Chiang HY, et al. The ratio and difference of urine protein-to-creatinine ratio and albumin-to-creatinine ratio facilitate risk prediction of all-cause mortality. Sci Rep. 2021. https:\/\/doi.org\/10.1038\/s41598-021-86541-333846379.","journal-title":"Sci Rep"},{"key":"2937_CR19","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s10067-024-07272-0","volume":"44","author":"M Tang","year":"2025","unstructured":"Tang M, Du L, Peng J. Urinary albumin-to-creatinine ratio for predicting risk of all-cause mortality and specific-cause mortality in patients with rheumatoid arthritis: evidence from NHANES 1999\u20132018. Clin Rheumatol. 2025;44:623\u201333. https:\/\/doi.org\/10.1007\/s10067-024-07272-0. (PubMed PMID: 39738846).","journal-title":"Clin Rheumatol"},{"key":"2937_CR20","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s10157-024-02600-9","volume":"29","author":"T Konta","year":"2025","unstructured":"Konta T, Asahi K, Tamura K, Tanaka F, Fukui A, Nakamura Y, et al. The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese non-diabetic patients. Clin Exp Nephrol. 2025;29:583\u201395. https:\/\/doi.org\/10.1007\/s10157-024-02600-9.","journal-title":"Clin Exp Nephrol"},{"key":"2937_CR21","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/ckj\/sfac036","volume":"15","author":"H Hanaoka","year":"2022","unstructured":"Hanaoka H, Kikuchi J, Hiramoto K, Saito S, Kondo Y, Kaneko Y. Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs. Clin Kidney J. 2022;15:1373\u20138. https:\/\/doi.org\/10.1093\/ckj\/sfac036.","journal-title":"Clin Kidney J"},{"key":"2937_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-022-02920-6","author":"W Pan","year":"2022","unstructured":"Pan W, Han Y, Hu H, He Y. Association between hemoglobin and chronic kidney disease progression: a secondary analysis of a prospective cohort study in Japanese patients. BMC Nephrol. 2022. https:\/\/doi.org\/10.1186\/s12882-022-02920-6.","journal-title":"BMC Nephrol"},{"key":"2937_CR23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1053\/j.ajkd.2022.07.014","volume":"81","author":"DK Farrington","year":"2023","unstructured":"Farrington DK, Sang Y, Grams ME, Ballew SH, Dunning S, Stempniewicz N, et al. Anemia prevalence, type, and associated risks in a cohort of 5.0 million insured patients in the United States by level of kidney function. Am J Kidney Dis. 2023;81:201-209.e1. https:\/\/doi.org\/10.1053\/j.ajkd.2022.07.014.","journal-title":"Am J Kidney Dis"},{"key":"2937_CR24","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.ard.2026.01.023","volume":"85","author":"JS Smolen","year":"2025","unstructured":"Smolen JS, Edwards CJ, Konzett V, Laskou F, Aletaha D, Caporali R, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update. Ann Rheum Dis. 2025;85:991\u20131009. https:\/\/doi.org\/10.1016\/j.ard.2026.01.023.","journal-title":"Ann Rheum Dis"},{"key":"2937_CR25","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1136\/rmdopen-2016","volume":"2","author":"JM Kremer","year":"2016","unstructured":"Kremer JM, Lawrence DA, Hamilton R, Mcinnes IB. Long-term study of the impact of methotrexate on serum cytokines and lymphocyte subsets in patients with active rheumatoid arthritis: correlation with pharmacokinetic measures. RMD Open. 2016;2:287. https:\/\/doi.org\/10.1136\/rmdopen-2016.","journal-title":"RMD Open"},{"key":"2937_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2025.2460267","author":"H Hanaoka","year":"2025","unstructured":"Hanaoka H, Aoki T, Kosaka T, Yoshinaga S, Shibata A, Sakai R, et al. Chronic kidney disease and inflammatory cytokines in rheumatoid arthritis: a potential pathogenic link. Immunol Med. 2025. https:\/\/doi.org\/10.1080\/25785826.2025.2460267.","journal-title":"Immunol Med"},{"key":"2937_CR27","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2021050598","author":"JA Sparks","year":"2021","unstructured":"Sparks JA, Vanni KMM, Sparks MA, Xu C, Santacroce LM, Glynn RJ, et al. Effect of low-dose methotrexate on estimated glomerular filtration rate and kidney adverse events: a randomized clinical trial. J Am Soc Nephrol. 2021. https:\/\/doi.org\/10.1681\/ASN.2021050598.","journal-title":"J Am Soc Nephrol"},{"key":"2937_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-75655-9","author":"K Hayashi","year":"2020","unstructured":"Hayashi K, Sada KE, Asano Y, Asano SH, Yamamura Y, Ohashi K, et al. Risk of higher dose methotrexate for renal impairment in patients with rheumatoid arthritis. Sci Rep. 2020. https:\/\/doi.org\/10.1038\/s41598-020-75655-9.","journal-title":"Sci Rep"},{"key":"2937_CR29","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","volume":"7","author":"HJL Heerspink","year":"2019","unstructured":"Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL, et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomized clinical trials. Lancet Diabetes Endocrinol. 2019;7:128\u201339. https:\/\/doi.org\/10.1016\/S2213-8587(18)30314-0.","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02937-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-026-02937-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02937-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T12:30:53Z","timestamp":1788006653000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-026-02937-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":29,"alternative-id":["2937"],"URL":"https:\/\/doi.org\/10.1007\/s10157-026-02937-3","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]},"assertion":[{"value":"23 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki. The study protocol was approved by the Ethics Review Committee of Kindai University Nara Hospital (No.833). As this was a retrospective observational study, the Ethics Review Committee waived the requirement for obtaining individual written consent.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this is a retrospective observational study, the Ethics Review Committee waived the requirement to obtain individual written consent.","order":3,"name":"Ethics","label":"Consent to participate in the study","group":{"name":"EthicsHeading","label":"Declarations"}}]}}